Journal article 277 views 44 downloads
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Leonardo Buttice
,
Maryam Ghani,
Janahan Suthakar,
Sathyan Gnanalingham,
Elliott Carande,
Brett W. C. Kennedy,
Alex Pitcher,
James H. P. Gamble
,
Mahmood Ahmad,
Andrew Lewis,
Peter Jüni,
Oliver J. Rider,
Jeffrey Stephens
,
Jonathan J. H. Bray
Diabetes, Obesity and Metabolism
Swansea University Author:
Jeffrey Stephens
-
PDF | Version of Record
© 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution License.
Download (5.03MB)
DOI (Published version): 10.1111/dom.15586
Abstract
AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammato...
Published in: | Diabetes, Obesity and Metabolism |
---|---|
ISSN: | 1462-8902 1463-1326 |
Published: |
Wiley
2024
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa66055 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2024-04-15T07:53:39Z |
---|---|
last_indexed |
2024-04-15T07:53:39Z |
id |
cronfa66055 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>66055</id><entry>2024-04-15</entry><title>The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials</title><swanseaauthors><author><sid>5219d126f97f8f884bdb622099bd41de</sid><ORCID>0000-0003-2228-086X</ORCID><firstname>Jeffrey</firstname><surname>Stephens</surname><name>Jeffrey Stephens</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-04-15</date><deptcode>MEDS</deptcode><abstract>AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow-up of 16 (12–24) weeks. Meta-analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin-6, tumour necrosis factor receptor-1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C-reactive protein (CRP), tumour necrosis factor-α, plasminogen activator inhibitor-1, fibroblast growth factor-21 or monocyte chemoattractant protein-1.ConclusionsOur analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP.</abstract><type>Journal Article</type><journal>Diabetes, Obesity and Metabolism</journal><volume>0</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1462-8902</issnPrint><issnElectronic>1463-1326</issnElectronic><keywords>cardiovascular disease, dapagliflozin, empagliflozin, inflammation, mechanism of action, sodium-glucose co-transporter-2 inhibitors</keywords><publishedDay>11</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-04-11</publishedDate><doi>10.1111/dom.15586</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>The authors received no funding.</funders><projectreference/><lastEdited>2024-05-22T12:27:41.7106696</lastEdited><Created>2024-04-15T08:49:54.0883585</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Leonardo</firstname><surname>Buttice</surname><orcid>0000-0003-3527-2172</orcid><order>1</order></author><author><firstname>Maryam</firstname><surname>Ghani</surname><order>2</order></author><author><firstname>Janahan</firstname><surname>Suthakar</surname><order>3</order></author><author><firstname>Sathyan</firstname><surname>Gnanalingham</surname><order>4</order></author><author><firstname>Elliott</firstname><surname>Carande</surname><order>5</order></author><author><firstname>Brett W. C.</firstname><surname>Kennedy</surname><order>6</order></author><author><firstname>Alex</firstname><surname>Pitcher</surname><order>7</order></author><author><firstname>James H. P.</firstname><surname>Gamble</surname><orcid>0000-0001-9905-3337</orcid><order>8</order></author><author><firstname>Mahmood</firstname><surname>Ahmad</surname><order>9</order></author><author><firstname>Andrew</firstname><surname>Lewis</surname><order>10</order></author><author><firstname>Peter</firstname><surname>Jüni</surname><order>11</order></author><author><firstname>Oliver J.</firstname><surname>Rider</surname><order>12</order></author><author><firstname>Jeffrey</firstname><surname>Stephens</surname><orcid>0000-0003-2228-086X</orcid><order>13</order></author><author><firstname>Jonathan J. H.</firstname><surname>Bray</surname><orcid>0000-0003-1167-6295</orcid><order>14</order></author></authors><documents><document><filename>66055__30217__088940e17bb74c09a0418f4fb3724075.pdf</filename><originalFilename>66055.pdf</originalFilename><uploaded>2024-05-01T14:29:19.0494506</uploaded><type>Output</type><contentLength>5277094</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
v2 66055 2024-04-15 The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials 5219d126f97f8f884bdb622099bd41de 0000-0003-2228-086X Jeffrey Stephens Jeffrey Stephens true false 2024-04-15 MEDS AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow-up of 16 (12–24) weeks. Meta-analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin-6, tumour necrosis factor receptor-1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C-reactive protein (CRP), tumour necrosis factor-α, plasminogen activator inhibitor-1, fibroblast growth factor-21 or monocyte chemoattractant protein-1.ConclusionsOur analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP. Journal Article Diabetes, Obesity and Metabolism 0 Wiley 1462-8902 1463-1326 cardiovascular disease, dapagliflozin, empagliflozin, inflammation, mechanism of action, sodium-glucose co-transporter-2 inhibitors 11 4 2024 2024-04-11 10.1111/dom.15586 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee The authors received no funding. 2024-05-22T12:27:41.7106696 2024-04-15T08:49:54.0883585 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Leonardo Buttice 0000-0003-3527-2172 1 Maryam Ghani 2 Janahan Suthakar 3 Sathyan Gnanalingham 4 Elliott Carande 5 Brett W. C. Kennedy 6 Alex Pitcher 7 James H. P. Gamble 0000-0001-9905-3337 8 Mahmood Ahmad 9 Andrew Lewis 10 Peter Jüni 11 Oliver J. Rider 12 Jeffrey Stephens 0000-0003-2228-086X 13 Jonathan J. H. Bray 0000-0003-1167-6295 14 66055__30217__088940e17bb74c09a0418f4fb3724075.pdf 66055.pdf 2024-05-01T14:29:19.0494506 Output 5277094 application/pdf Version of Record true © 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution License. true eng http://creativecommons.org/licenses/by/4.0/ |
title |
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials |
spellingShingle |
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials Jeffrey Stephens |
title_short |
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials |
title_full |
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials |
title_fullStr |
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials |
title_full_unstemmed |
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials |
title_sort |
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials |
author_id_str_mv |
5219d126f97f8f884bdb622099bd41de |
author_id_fullname_str_mv |
5219d126f97f8f884bdb622099bd41de_***_Jeffrey Stephens |
author |
Jeffrey Stephens |
author2 |
Leonardo Buttice Maryam Ghani Janahan Suthakar Sathyan Gnanalingham Elliott Carande Brett W. C. Kennedy Alex Pitcher James H. P. Gamble Mahmood Ahmad Andrew Lewis Peter Jüni Oliver J. Rider Jeffrey Stephens Jonathan J. H. Bray |
format |
Journal article |
container_title |
Diabetes, Obesity and Metabolism |
container_volume |
0 |
publishDate |
2024 |
institution |
Swansea University |
issn |
1462-8902 1463-1326 |
doi_str_mv |
10.1111/dom.15586 |
publisher |
Wiley |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science |
document_store_str |
1 |
active_str |
0 |
description |
AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow-up of 16 (12–24) weeks. Meta-analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin-6, tumour necrosis factor receptor-1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C-reactive protein (CRP), tumour necrosis factor-α, plasminogen activator inhibitor-1, fibroblast growth factor-21 or monocyte chemoattractant protein-1.ConclusionsOur analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP. |
published_date |
2024-04-11T12:27:41Z |
_version_ |
1799752003013836800 |
score |
11.021648 |